INTRAVENOUS METHYLPREDNISOLONE VS ORAL PREDNISOLONE IN TRANSPLANT REJECTION

静脉注射甲基泼尼松龙与口服泼尼松龙在移植排斥中的比较

• 批准号: 7374506
• 负责人: GREGORY M TIAO
• 金额: $ 0.06万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7374506
• 关键词: INTRAVENOUS; METHYLPREDNISOLONE; VS; ORAL; PREDNISOLONE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The trial comparing intravenous methlyprednisolone versus oral prednisolone in the treatment of acute rejection in pediatric liver transplant recipients continues. We are comparing the effect of oral versus iv steroids in an effort to improve the patients quality of life and to reduce medical costs. In the past, all children who had acute rejection following liver transplantation required one week hospitalization. This is disruptive to their day to day life and has an impact on medical costs. The bioavailability of orally administered steroids is similar to those given intravenously therefore we hypothesized both treatments are effective. To ensure patient safety, we began this small study to test that hypothesis. Our study endpoints are control of acute rejection, improved quality of life as assessed by an outcomes questionnaire and decreased medical cost.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。该试验比较了静脉注射甲基甲硅醇与口服泼尼松龙在小儿肝移植受者中急性排斥反应中的试验继续进行。我们正在比较口服与IV类固醇的作用，以提高患者生活质量并降低医疗费用。过去，所有在肝移植后急性拒绝的孩子都需要一周的住院治疗。这对他们的日常生活具有破坏性，并对医疗费用产生影响。口服类固醇的生物利用度与静脉注射的类固醇相似，因此我们假设两种治疗方法都是有效的。为了确保患者的安全，我们开始了这项小型研究以检验该假设。我们的研究终点是控制急性排斥，改善生活质量，如结果调查表评估和医疗成本降低。